Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIO trial of ctDNA-guided olaparib in relapsed ovarian cancer
2015-005838-22Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in ovarian cancer, sponsored by UZ Leuven. Primary endpoint: Overall objective response rate. Started Jun 2016; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2015-005838-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005838-22.